Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what discussions his Department has had with representatives of Eusa Pharma on the availability of Dinutuximab Beta on the NHS.

Departmental officials have had no such discussions. However, representatives of the National Institute for Health and Care Excellence are in regular contact with Eusa Pharma in the context of the ongoing technology appraisal of dinutuximab beta for the treatment of high risk neuroblastoma.